80 related articles for article (PubMed ID: 3137644)
21. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
22. Peak cerebrospinal fluid platinum levels in a patient with ependymoma: evaluation of two different methods of cisplatin administration.
DeGregorio M; Wilbur B; King O; Wallenberg J; Prewitt S; Phillips J; Wilbur J
Cancer Treat Rep; 1986 Dec; 70(12):1437-8. PubMed ID: 3791256
[TBL] [Abstract][Full Text] [Related]
23. [An early phase II trial combining cisplatin and carboplatin in advanced non-small cell lung cancer].
Yoshimura A; Yamano Y; Gemma A; Yoshimori K; Hayashihara K; Taniguchi Y; Uematsu K; Shibuya M; Kudoh S; Niitani H
Gan To Kagaku Ryoho; 1993 Mar; 20(4):503-8. PubMed ID: 8383951
[TBL] [Abstract][Full Text] [Related]
24. Milk production in cows with endotoxin-induced mastitis treated with isotonic or hypertonic sodium chloride solution.
Tyler JW; DeGraves FJ; Erskine RJ; Riddell MG; Lin HC; Kirk JH
J Am Vet Med Assoc; 1994 Jun; 204(12):1949-52. PubMed ID: 8077143
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of nephrotoxicosis associated with a four-hour saline solution diuresis protocol for the administration of cisplatin to dogs with naturally developing neoplasms.
Ogilvie GK; Straw RC; Jameson VJ; Walters LM; Lafferty M; Powers BE; Henkel SE; Withrow SJ
J Am Vet Med Assoc; 1993 Jun; 202(11):1845-8. PubMed ID: 8320153
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of cisplatin in combination with glutathione.
Plaxe S; Freddo J; Kim S; Kirmani S; McClay E; Christen R; Braly P; Howell S
Gynecol Oncol; 1994 Oct; 55(1):82-6. PubMed ID: 7959273
[TBL] [Abstract][Full Text] [Related]
27. [Wrapping in damp cloth, drinking electrolytes or infusions. What to do when fit men collapse?].
Huonker M
MMW Fortschr Med; 2003 Sep; 145(37):49-51. PubMed ID: 14584445
[No Abstract] [Full Text] [Related]
28. Use of hypertonic saline in ischemic stroke.
Ziai WC; Mirski MA; Bhardwaj A
Stroke; 2002 Apr; 33(4):1166-7; author reply 1166-7. PubMed ID: 11935080
[No Abstract] [Full Text] [Related]
29. [Urinary lysozyme, beta-2-microglobulin, and alpha-glucosidase during cisplatin therapy].
Airoldi M; Pecchio F; Albanese F; Mastromatteo V; Gariboldi A; Di Costanzo G; Fazio M
Boll Soc Ital Biol Sper; 1983 Mar; 59(3):392-8. PubMed ID: 9704142
[No Abstract] [Full Text] [Related]
30. Evaluation of ethanol as an antiemetic in patients receiving cisplatin.
Spiess JL; Adelstein DJ; Hines JD
Clin Ther; 1987; 9(4):400-4. PubMed ID: 3607821
[TBL] [Abstract][Full Text] [Related]
31. Tolerability and efficacy of high-dose furosemide and small-volume hypertonic saline solution in refractory congestive heart failure.
Paterna S; Parrinello G; Amato P; Dominguez L; Pinto A; Maniscalchi T; Cardinale A; Licata A; Amato V; Licata G; Di Pasquale P
Adv Ther; 1999; 16(5):219-28. PubMed ID: 10915397
[TBL] [Abstract][Full Text] [Related]
32. Safe, rapid administration of cisplatin in the outpatient clinic.
Brock J; Alberts DS
Cancer Treat Rep; 1986 Dec; 70(12):1409-14. PubMed ID: 3539327
[TBL] [Abstract][Full Text] [Related]
33. Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis.
Agostinucci WA; Gannon RH; Golub GR; Martin RS; Schauer PK; Dinonno EB
Clin Pharm; 1988 Jun; 7(6):454-7. PubMed ID: 3402181
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study.
Pratt CB; Hayes A; Green AA; Evans WE; Senzer N; Howarth CB; Ransom JL; Crom W
Cancer Treat Rep; 1981; 65(11-12):1021-6. PubMed ID: 7197583
[TBL] [Abstract][Full Text] [Related]
35. Dose-limiting myelosuppression associated with high-dose cisplatin (200 mg/m2) in hypertonic saline.
Gandara DR; Mansour R; Wold H; George C
Cancer Treat Rep; 1986 Jun; 70(6):820-1. PubMed ID: 3731145
[No Abstract] [Full Text] [Related]
36. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M;
Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762
[TBL] [Abstract][Full Text] [Related]
37. [Use of prolonged intravenous infusions of cisplatin in patients with malignant neoplasms].
Tiuliadin SA
Vopr Onkol; 1983; 29(12):40-4. PubMed ID: 6582683
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.
Bajorin DF; Bosl GJ; Alcock NW; Niedzwiecki D; Gallina E; Shurgot B
Cancer Res; 1986 Nov; 46(11):5969-72. PubMed ID: 3756934
[TBL] [Abstract][Full Text] [Related]
39. [Postoperative infusion in patients with urinary calculi during comparative treatment with using mannitol and furosemide].
Wiederhold EM; Schneider HJ; Hesse A
Z Urol Nephrol; 1974 Feb; 67(2):99-109. PubMed ID: 4849436
[No Abstract] [Full Text] [Related]
40. Cisplatin: a review of clinical applications and renal toxicity.
Sleijfer DT; Meijer S; Mulder NH
Pharm Weekbl Sci; 1985 Dec; 7(6):237-44. PubMed ID: 3909096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
